1. Academic Validation
  2. Production of a new hybrid anthracycline 4-O-methylepelmycin by heterologous expression of dnrK in epelmycin-producing Streptomyces violaceus

Production of a new hybrid anthracycline 4-O-methylepelmycin by heterologous expression of dnrK in epelmycin-producing Streptomyces violaceus

  • J Antibiot (Tokyo). 2000 Aug;53(8):828-36. doi: 10.7164/antibiotics.53.828.
Y Miyamoto 1 S Ohta O Johdo Y Nagamatsu A Yoshimoto
Affiliations

Affiliation

  • 1 Faculty of Applied Biological Science, Hiroshima University, Higashi-Hiroshima, Japan.
Abstract

A new hybrid anthracycline Antibiotic was produced by heterologous expression of dnrK encoding carminomycin 4-O-metyltransferase in an epelmycin-producing Streptomyces violaceus. pMK100 was constructed by insertion of Steptomyces peucetius dnrK gene in Steptomyces-expression vector pIJ6021 and introduced to the epelmycin producer. The transformant produced a hybrid anthracycline Antibiotic together with host epelmycins when cultured in Antibiotic production medium in the presence of thiostrepton. The hybrid anthracycline was determined to be 7-O-L-rhodosaminyl-4-O-methyl-epsilon-rhodomycinone (4-O-methylepelmycin D). However, the attempts on production of hybrid 4-O-methylaclarubicin and 4-O-methyl-1-deoxyobelmycin by the transformants of aclarubicin and 1-deoxyobelmycin producers with pMK 100 were unsuccessful.

Figures
Products